JMP Securities Downgrades Arbutus Biopharma (ABUS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Wedbush Downgrades Arbutus Biopharma (ABUS) to Underperform
October 9, 2018 10:10 AM EDTWedbush analyst Robert Driscoll downgraded Arbutus Biopharma (NASDAQ: ABUS) from Neutral to Underperform with a price target of $5.00 (from $7.00).
For an analyst ratings summary and ratings history on Arbutus Biopharma click here. For more ratings news on Arbutus Biopharma click here.
Shares of Arbutus Biopharma closed at $9.09 yesterday.
... More